Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: a subset analysis of the PRISTINE trial

BMC Family Practice

E. Aldinç⁴  E. Y. Mahgoub⁷  L. Marshall⁷  A. Szumski⁷  W-R. Lee²  N. Rajatanavin⁵  P. Cetkovska⁶  M. Amaya¹  L. Kemeny³ 

[1] Hospital San Lucas, Monterrey, Nuevo Leon, Mexico;Department of Dermatology, Shuang Ho Hospital, Taipei, Taiwan;Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary;Global Innovative Pharma, Pfizer, New York, NY, USA;Division of Dermatology, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;Department of Dermatovenereology, Charles University Hospital, Pilsen, Czech Republic;Global Innovative Pharma, Pfizer, Collegeville, PA, USA

关键词: Latin America;    Central Europe;    Asia;    Psoriasis treatment;    Etanercept;   

Others  :  1210945
DOI  :  10.1186/s12895-015-0028-8

 received in 2014-11-10, accepted in 2015-05-04,  发布年份 2015

【 摘 要 】

Background

Psoriasis prevalence and characteristics in Asia, Central Europe, and Latin America have not been thoroughly investigated and there are no large trials for biologic treatments for patients from these regions. The goal of this analysis was to report clinical response to anti-tumor necrosis factor-alpha treatment in these patients.

Methods

Patients from Argentina, Czech Republic, Hungary, Mexico, Taiwan, and Thailand (N = 171) were included in this subset analysis of the PRISTINE trial. Patients with stable moderate-to-severe plaque psoriasis were blinded and randomized to receive etanercept 50 mg once weekly (QW) or biweekly (BIW) for 12 weeks, followed by 12 weeks of open-label QW treatment with etanercept 50 mg through week 24 (QW/QW vs. BIW/QW). Concomitant methotrexate (≤20 mg/week) and mild topical corticosteroids or other agents were permitted at the physician’s discretion, in accordance with therapeutic practice.

Results

As early as week 8, 26.7 % in the etanercept QW group and 44.0 % in the BIW group achieved Psoriasis Area and Severity Index (PASI) 75. At weeks 12 and 24, respectively, PASI 75 increased to 39.5 % and 62.8 % in the QW/QW group and 66.7 % and 83.3 % in the BIW/QW group. PASI 75 was significantly different between treatment groups from week 8 through the end of study (p < 0.05). The Kaplan-Meier estimate of the proportions achieving PASI 75 in QW/QW and BIW/QW groups, respectively, was 27.4 % and 45.8 % through week 8; 41.9 % and 68.7 % through week 12; and 72.5 % and 95.2 % through week 24.

Conclusions

Treatment with etanercept 50 mg provided rapid relief of psoriasis symptoms in patients from Asia, Central Europe, and Latin America. A more rapid response was observed in patients who received BIW treatment for the first 12 weeks which was sustained after reducing to QW dosing for the subsequent 12 weeks. Response rates were similar to those observed in the overall PRISTINE population.

Trial registration

ClinicalTrials.gov identifier NCT00663052 webcite.

【 授权许可】

   
2015 Kemeny et al.; licensee BioMed Central.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

【 参考文献 】

• [1]Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014; 70(3):512-6.
• [2]Ding X, Wang T, Shen Y, Wang X, Zhou C, Tian S et al.. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol. 2012; 22(5):663-7.
• [3]Nast A, Boehncke W-H, Mrowietz U, Ockenfels H-M, Philipp S, Reich K et al.. S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update. J German Soc Dermatol. 2012; 10:S1-s95.
• [4]Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB et al.. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010; 62(1):114-35.
• [5]Smith CH, Anstey AV, Barker JNWN, Burden AD, Chalmers RJG, Chandler DA et al.. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009; 161(5):987-1019.
• [6]Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB et al.. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008; 58(5):826-50.
• [7]Menter A. The status of biologic therapies in the treatment of moderate to severe psoriasis. Cutis. 2009; 84(4 Suppl):14-24.
• [8]Strohal R, Puig L, Chouela E, Tsai TF, Melin J, Freundlich B et al.. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). J Dermatolog Treat. 2013; 24(3):169-78.
• [9]Badia X, Mascaro JM, Lozano R. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. The Cavide Research Group. Br J Dermatol. 1999; 141(4):698-702.
• [10]EuroQol--a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy. 1990; 16(3):199–208.
• [11]Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001; 33(5):337-43.
• [12]Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993; 4(5):353-65.
• [13]Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes. 2003; 1:79. BioMed Central Full Text
• [14]Cetkovská P, Kojanová M. Czech recommendations for biological therapy of severe plaque psoriasis. Čes-slov Derm. 2012; 87(1):1-76.
• [15]Amaya-Guerra M, Barba F, Blancas González F, Gómez Flores M, Gómez Trigo A, González Soto R et al.. Consenso Mexicano para el Manejo de Terapia Biológica en Psoriasis. Rev Cent Dermatol Pascua. 2004; 13(3):172-84.